Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X:
“Illustration of China making variants to infinite: PD-1 x VEGF wasn’t enough so somone’s trying PD-1 x VEGF x CTLA-4.
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody.”
More posts featuring Bertrand Delsuc.